A new resource is now available to download for free. MASLD drug development is limited by models that don’t reflect human liver biology. HUB’s patient-derived liver organoids retain donor genetics, architecture and physiology. Download the Factsheet to learn: How organoids recapitulate steatosis and fibrosis Which readouts support target validation… Read More
Boost your drug discovery with 3D spheroid models and live-cell analysis – perfect for screening thousands of compounds! A new App Note is now available from Sartorius entitled ‘Enhance Drug Discovery: Utilising a 3D Spheroid Model and Live-Cell Analysis for Compound Profiling’. Download the App Note to learn: How… Read More
This is the latest episode of the free DDW Narrated Podcast, called “How new scientific approaches are accelerating R&D”. The episode covers two articles written for DDW Volume 25, Issue 1, Winter 2023/24. The first article is called ‘Accelerating recombinant protein vaccine discovery’. In the… Read More
Boost your drug discovery with 3D spheroid models and live-cell analysis – perfect for screening thousands of compounds! Download the App Note to learn: How to capture dynamic cellular changes in real time How to understand the advantages of 3D assays over traditional 2D models About advanced imaging and analysis… Read More
3D spheroid models and live-cell analysis are powerful tools transforming drug discovery and cancer science. Download this eBook ‘Exploring the Versatility of Using 3D Spheroid Models in Research‘ from Sartorius to learn: How real-time imaging unlocks deeper insights Discover why 3D models outperform traditional cultures How to create more… Read More
3D spheroid models and live-cell analysis – powerful tools transforming drug discovery and cancer science! Download the eBook to learn: How real-time imaging unlocks deeper insights Discover why 3D models outperform traditional cultures How to create more reliable, clinically relevant cancer models Download now and accelerate your breakthroughs. … Read More
Dr Todd Dickinson, CEO, Stellaromics on 3D spatial biology and functional genomics. Understanding how genes are regulated and expressed in complex tissue environments is fundamental to modern drug discovery. Traditionally, researchers have relied on 2D spatial genomics methods, analysing thin slices of tissue on a single plane to study gene… Read More
Balancing assay throughput with physiological relevance is essential for improving disease modelling and compound screening in preclinical drug development. Induced pluripotent stem cell (iPSC) technology has revolutionised early drug discovery by integrating human biology, enhancing predictions of drug safety and efficacy. However, achieving both scalability and consistency in… Read More
Balancing assay throughput with physiological relevance is essential for improving disease modelling and compound screening in preclinical drug development. Induced pluripotent stem cell (iPSC) technology has revolutionised early drug discovery by integrating human biology, enhancing predictions of drug safety and efficacy. However, achieving both scalability and consistency in… Read More
Balancing assay throughput with physiological relevance is essential for improving disease modelling and compound screening in preclinical drug development. Induced pluripotent stem cell (iPSC) technology has revolutionised early drug discovery by integrating human biology, enhancing predictions of drug safety and efficacy. However, achieving both scalability and consistency in… Read More
Balancing assay throughput with physiological relevance is essential for improving disease modelling and compound screening in preclinical drug development. Induced pluripotent stem cell (iPSC) technology has revolutionised early drug discovery by integrating human biology, enhancing predictions of drug safety and efficacy. However, achieving both scalability and consistency in… Read More
Balancing assay throughput with physiological relevance is essential for improving disease modelling and compound screening in preclinical drug development. Induced pluripotent stem cell (iPSC) technology has revolutionised early drug discovery by integrating human biology, enhancing predictions of drug safety and efficacy. However, achieving both scalability and consistency in… Read More
DDW Editor Reece Armstrong looks at how advances in stem cells, organoids and 3D cell cultures are affecting drug discovery and development. Stem cells, organoids and 3D cell cultures have emerged as promising tools that scientists can use to better understand disease and how drugs function within the human… Read More
Scientists at the Cancer Research Manchester Institute have created a new model of Lung Squamous Cell Carcinoma (LUSC) to study the development, activity, and vulnerabilities of the disease. In the UK, around 80 to 85% of lung cancers are non-small cell lung cancer, of which squamous cell… Read More
Balancing assay throughput with physiological relevance is essential for improving disease modelling and compound screening in preclinical drug development. Induced pluripotent stem cell (iPSC) technology has revolutionised early drug discovery by integrating human biology, enhancing predictions of drug safety and efficacy. However, achieving both scalability and consistency in… Read More
Balancing assay throughput with physiological relevance is essential for improving disease modelling and compound screening in preclinical drug development. Induced pluripotent stem cell (iPSC) technology has revolutionised early drug discovery by integrating human biology, enhancing predictions of drug safety and efficacy. However, achieving both scalability and consistency in high-throughput applications… Read More
